openPR Logo
Press release

Biosimilar Interleukins Global Market Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast To 2033

Biosimilar Interleukins Global Market

Biosimilar Interleukins Global Market

The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2023 to $5.41 billion in 2024 at a compound annual growth rate (CAGR) of 39.0%. The growth in the historic period can be attributed to rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, increasing patient demand for biosimilars.

The biosimilar interleukins market size is expected to see exponentially grown in the next few years. It will grow to $20.79 billion in 2028 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to growing patient population, increased access to healthcare, growing demand for personalized medicine, growing demand for minimally invasive procedures. Major trends in the forecast period include advances in biosimilar technology, targeted immunotherapies, quality control and manufacturing, global collaboration.

Market Overview -
Biosimilar interleukins are defined as a biosimilar produced by the body's leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp

Surging Autoimmune Diseases Propel Growth In Interleukin Biosimilars Market
The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefits in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to a Johns Hopkins University report published in 2021, autoimmune diseases affected approximately 3% of the population in the United States or approximately 10 million people. Therefore the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

Competitive Landscape -
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sorrento Therapeutics, Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Biogen Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Mylan N.V.

Biogen Launches Tofidence, An Innovative Biologic Treatment
Major companies operating in the biosimilar interleukins market are innovating new products such as Tofidence (tocilizumab-bavi) to increase their profitability in the market.Tofidence is a monoclonal antibody that targets and attaches to interleukin-6 receptors, employed in the treatment of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen, a US-based biotechnology company got approval from the FDA for Tofidence (tocilizumab-bavi) as the first biosimilar to reference Genentech's Actemra (tocilizumab).Tofidence is administered through intravenous infusion and has received approval for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report

Key Segments -
The biosimilar interleukins market covered in this report is segmented -
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Interleukins Global Market Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast To 2033 here

News-ID: 3476126 • Views:

More Releases from The Business research company

Top Companies and Industry Competition in the Private Jet Charter Services Market
Top Companies and Industry Competition in the Private Jet Charter Services Marke …
The private jet charter services market is on a trajectory of significant expansion, fueled by evolving consumer preferences and technological innovations. With luxury travel gaining popularity and new digital solutions simplifying bookings, this sector is set to undergo remarkable changes in the coming years. Let's explore the market's projected growth, key players, emerging trends, and important segments shaping its future. Projected Expansion and Market Size of Private Jet Charter Services The
Overview of Segmentation, Market Trends, and Competitive Landscape in the Plasma Rocket Propulsion Market
Overview of Segmentation, Market Trends, and Competitive Landscape in the Plasma …
The plasma rocket propulsion market is gaining significant traction as space exploration and satellite deployment continue to advance rapidly. Innovations in propulsion technologies are driving new possibilities for long-duration missions and efficient satellite maneuvering. Below, we explore the market's projected growth, key players, emerging trends, and the main segments shaping this dynamic industry. Projected Expansion and Market Size for Plasma Rocket Propulsion The plasma rocket propulsion market is poised for substantial
Segmentation, Major Trends, and Competitive Overview of the Space Resource Utilization Market
Segmentation, Major Trends, and Competitive Overview of the Space Resource Utili …
The exploration and utilization of space resources is rapidly evolving into a promising sector with vast potential for growth and innovation. As technology advances and partnerships form, the industry is set to transform how humanity accesses and uses materials beyond Earth, paving the way for sustainable off-world operations and broader space exploration. Projected Market Growth for Space Resource Utilization The space resource utilization industry is anticipated to experience significant expansion over
Market Trend Analysis: The Impact of Recent Advances on the Space Law Enforcement Market
Market Trend Analysis: The Impact of Recent Advances on the Space Law Enforcemen …
The growing complexity and activity in outer space have brought increased attention to the need for effective space law enforcement. As the number of satellites and space missions rises, managing space traffic and ensuring compliance with regulations becomes critical. This overview explores the future outlook, driving factors, major players, and structural breakdown of the space law enforcement market as it progresses toward 2030. Expected Growth Trajectory of the Space Law Enforcement

All 5 Releases


More Releases for Biosimilar

Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period View sample report https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023 The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market? In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030." Get
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031." The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of